22nd May 2015
Following work conducted in the Vectura- Nuformix collaboration, Nuformix has been awarded a follow-up SMART award to develop cocrystal-enabled dry powder inhaler (DPI) formulations at its Cambridge R&D facility. Nuformix Chief Executive Officer Dr Dan Gooding said: “Our collaboration with Vectura gave us a unique insight into how cocrystal technology can be exploited in DPI drug delivery. The field is relatively unexploited and we’re delighted to receive further IUK support to develop cocrystal-enabled DPI’s up to pre-clinical stage”.